MAP2K4

DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

Retrieved on: 
Wednesday, October 20, 2021

MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.

Key Points: 
  • MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
  • Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
  • About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
    The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.